tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hand Dermatoses D006229 5 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Gout D006073 4 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Ovarian Cysts D010048 4 associated lipids
Parotitis D010309 4 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Confusion D003221 4 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Bone Diseases D001847 4 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Eczema D004485 4 associated lipids
Foot Ulcer D016523 4 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Neuritis D009443 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Headache D006261 4 associated lipids
Pain, Intractable D010148 4 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Balanitis D001446 4 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Amenorrhea D000568 4 associated lipids
Blepharitis D001762 4 associated lipids
Diabetes Complications D048909 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Hallucinations D006212 4 associated lipids
Meningoencephalitis D008590 4 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Prurigo D011536 4 associated lipids
Viremia D014766 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Siekierka JJ et al. Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. 1991 Transplant. Proc. pmid:1721256
Morris RE In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. 1991 Transplant. Proc. pmid:1721257
Kobayashi M et al. FK 506 assay past and present--characteristics of FK 506 ELISA. 1991 Transplant. Proc. pmid:1721258
Warty VS et al. Practical aspects of FK 506 analysis (Pittsburgh experience). 1991 Transplant. Proc. pmid:1721259
Francavilla A et al. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. 1991 Transplant. Proc. pmid:1721287
Blanc P et al. Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. 1991 Transplant. Proc. pmid:1721288
Loréal O et al. FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. 1991 Transplant. Proc. pmid:1721289
McCauley J et al. Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. 1991 Transplant. Proc. pmid:1721290
Chen-Woan M et al. Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721320
Fukuzawa M et al. Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. 1991 Transplant. Proc. pmid:1721321
Takaori K et al. Effects of FK 506 on in vivo immunity in comparison to cyclosporine. 1991 Transplant. Proc. pmid:1721322
Jordan ML et al. Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. 1991 Transplant. Proc. pmid:1721323
Alessiani M et al. CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721351
Green M et al. Infectious complications of pediatric liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721352
Carroll PB et al. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. 1991 Transplantation pmid:1702911
Torre-Cisneros J et al. The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. 1991 Transplant. Proc. pmid:1721353
Starzl TE et al. Hepatotrophic effects of FK506 in dogs. 1991 Transplantation pmid:1702912
Paul AA et al. CMV retinitis and the use of FK 506. 1991 Transplant. Proc. pmid:1721354
Keicho N et al. Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. 1991 Cell. Immunol. pmid:1703047
Moutabarrik A et al. In vitro FK 506 kidney tubular cell toxicity. 1991 Transplant. Proc. pmid:1721383
McCauley J et al. Changes in renal function after liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721385
Tauxe WN et al. A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. 1991 Transplant. Proc. pmid:1721386
McCauley J et al. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. 1991 Transplant. Proc. pmid:1721387
Fukuzaki T et al. Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. 1991 Transplant. Proc. pmid:1721415
Tzakis AG et al. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. 1991 Transplant. Proc. pmid:1721416
Masaoka T et al. Phase II study of FK 506 for allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721417
Markus PM et al. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721418
de Paulis A et al. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. 1991 J. Immunol. pmid:1706398
Griffiths EJ and Halestrap AP Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. 1991 Biochem. J. pmid:1706598
Brabletz T et al. The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. 1991 Nucleic Acids Res. pmid:1707162
Propper DJ et al. Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. 1991 Transplant. Proc. pmid:1721446
Fabrega AJ et al. FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. 1991 Transplant. Proc. pmid:1721447
Davies CB et al. Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. 1991 Transplant. Proc. pmid:1721448
Abu-Elmagd K et al. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. 1991 Transplant. Proc. pmid:1721449
Miyahara H et al. Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. 1991 Clin. Immunol. Immunopathol. pmid:1712688
McAlpine JB et al. Revised NMR assignments for rapamycin. 1991 J. Antibiot. pmid:1712766
Banerji SS et al. The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. 1991 Mol. Cell. Biol. pmid:1712901
Markus PM et al. FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. 1991 Surgery pmid:1713358
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Ochiai T et al. [Immunosuppressive agents--advances of the developmental studies and the mode of action]. 1991 Nippon Rinsho pmid:1715926
Ricordi C et al. In vivo effect of FK506 on human pancreatic islets. 1991 Transplantation pmid:1716797
Katz IA et al. Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. 1991 Transplantation pmid:1716801
Jiang H et al. Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. 1991 Eur Surg Res pmid:1723683
Pezze JL and Whiteman K Transplantation's newest weapon FK 506. 1991 Am J Nurs pmid:1716857
Fung JJ et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. 1991 Transplant. Proc. pmid:1703682
Marquis-Omer D et al. Stabilization of the FK506 binding protein by ligand binding. 1991 Biochem. Biophys. Res. Commun. pmid:1716886
Nakahama H et al. Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. 1991 J. Cardiovasc. Pharmacol. pmid:1725322
Romanowski P et al. [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. 1991 Postepy Biochem. pmid:1725924
Altmeyer A et al. Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. 1991 Int. J. Immunopharmacol. pmid:1726093
Gordon RD et al. Liver transplantation at the University of Pittsburgh, 1984 to 1990. 1991 Clin Transpl pmid:1726458